Trial Outcomes & Findings for Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 1 (NCT NCT04527978)

NCT ID: NCT04527978

Last Updated: 2021-11-23

Results Overview

Distance VA was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity. No formal hypothesis was predefined for the primary endpoint. No inferential testing was performed.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

56 participants

Primary outcome timeframe

Day 8 (-0/+3 days) after 10 (-2/+6) hours of wear, each study lens type

Results posted on

2021-11-23

Participant Flow

Subjects were recruited from 4 investigative sites located in the United States.

Of the 56 subjects enrolled in the study, 1 subject was discontinued after randomization and prior to exposure to the study lenses. This reporting group includes all randomized and exposed subjects (55).

Unit of analysis: eyes

Participant milestones

Participant milestones
Measure
PRECISION1, Then Biotrue ONEday
Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
Biotrue ONEday, Then PRECISION1
Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
First Wear Period (8 -0/+3 Days)
STARTED
27 54
28 56
First Wear Period (8 -0/+3 Days)
COMPLETED
26 52
28 56
First Wear Period (8 -0/+3 Days)
NOT COMPLETED
1 2
0 0
Second Wear Period (8 -0/+3 Days)
STARTED
26 52
28 56
Second Wear Period (8 -0/+3 Days)
COMPLETED
26 52
28 56
Second Wear Period (8 -0/+3 Days)
NOT COMPLETED
0 0
0 0

Reasons for withdrawal

Reasons for withdrawal
Measure
PRECISION1, Then Biotrue ONEday
Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
Biotrue ONEday, Then PRECISION1
Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
First Wear Period (8 -0/+3 Days)
Adverse Event
1
0

Baseline Characteristics

Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 1

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PRECISION1, Then Biotrue ONEday
n=27 Participants
Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
Biotrue ONEday, Then PRECISION1
n=28 Participants
Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
Total
n=55 Participants
Total of all reporting groups
Age, Continuous
33.7 years
STANDARD_DEVIATION 6.3 • n=99 Participants
34.3 years
STANDARD_DEVIATION 8.9 • n=107 Participants
34.0 years
STANDARD_DEVIATION 7.7 • n=206 Participants
Sex: Female, Male
Female
20 Participants
n=99 Participants
25 Participants
n=107 Participants
45 Participants
n=206 Participants
Sex: Female, Male
Male
7 Participants
n=99 Participants
3 Participants
n=107 Participants
10 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=99 Participants
1 Participants
n=107 Participants
4 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants
n=99 Participants
27 Participants
n=107 Participants
51 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
White
25 Participants
n=99 Participants
26 Participants
n=107 Participants
51 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Region of Enrollment
United States
27 participants
n=99 Participants
28 participants
n=107 Participants
55 participants
n=206 Participants

PRIMARY outcome

Timeframe: Day 8 (-0/+3 days) after 10 (-2/+6) hours of wear, each study lens type

Population: Safety Analysis Set with non-missing response

Distance VA was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity. No formal hypothesis was predefined for the primary endpoint. No inferential testing was performed.

Outcome measures

Outcome measures
Measure
PRECISION1
n=108 eyes
Verofilcon A contact lenses worn bilaterally (in both eyes) during Period 1 or Period 2, as randomized, for 8 -0/+3 days in a daily disposable modality
Biotrue ONEday
n=108 eyes
Nesofilcon A contact lenses worn bilaterally (in both eyes) during Period 1 or Period 2, as randomized, for 8 -0/+3 days in a daily disposable modality
Distance Visual Acuity (VA) With Study Lenses
-0.13 logMAR
Standard Deviation 0.08
-0.12 logMAR
Standard Deviation 0.08

Adverse Events

Pretreatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

PRECISION1 Ocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

PRECISION1 Nonocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Biotrue ONEday Ocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Biotrue ONEday Nonocular

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

CDMA Project Lead, Vision Care

Alcon Research, LLC

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee Sponsor reserves the right of prior review of any publication or presentation of information related to the study.
  • Publication restrictions are in place

Restriction type: OTHER